Kiromic Biopharma (KRBP) AI Stock Analysis

• Market Cap: $265.35K
• Dividend Yield: N/A
• Average Volume (3M): 12.53K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.50
• Revenue Growth: N/A
• EPS Growth: -4.26%
• Country: US
• Employees: 44
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -22.86
• Shares Outstanding: 2,653,479
• 10 Day Avg. Volume: 36,564
• 30 Day Avg. Volume: 12,525
• PEG Ratio: -0.04
• Price to Book (P/B): -2.47
• Price to Sales (P/S): N/A
• P/FCF Ratio: -0.15
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

The company's primary challenges are financial instability and a lack of revenue, with significant reliance on external financing. The technical analysis suggests bearish momentum, and the negative P/E ratio reflects financial distress. Immediate strategic changes are necessary to improve its position.

Kiromic Biopharma Business Overview & Revenue Model

Company Description

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

How the Company Makes Money

Kiromic Biopharma makes money primarily through the development and commercialization of its immuno-oncology products. The company generates revenue by licensing its technology platforms and collaborating with pharmaceutical companies to develop new cancer therapies. Key revenue streams include milestone payments from partnerships, research funding, and eventually, product sales if their therapies receive regulatory approval. Significant factors contributing to its earnings include successful clinical trial results and strategic alliances with larger biotech or pharmaceutical companies, which can provide both financial support and expanded market reach.

Kiromic Biopharma Financial Statement Overview

Summary

Kiromic Biopharma is struggling financially, with no revenue, increasing losses, negative equity, and poor cash flow metrics. The company's reliance on financing to sustain operations poses significant risks. Immediate strategic pivots or funding solutions are essential to ensure long-term viability.

Income Statement

Kiromic Biopharma has not generated any revenue over the past years, and its net losses have been increasing. Operating losses are significant, reflecting high research and development expenses typical in biotech. The absence of revenue and growing losses are concerning for financial sustainability.

Balance Sheet

The company has a negative stockholders' equity, indicating liabilities exceed assets. This is a red flag for financial health. High debt levels relative to equity suggest potential solvency issues. The consistent negative equity ratio is a major risk factor.

Cash Flow

Cash flow from operations is consistently negative, indicating poor cash generation from core activities. Free cash flow is also negative, suggesting the company relies heavily on external financing for operations. Despite significant financing inflows, the sustainability of such cash flows is questionable.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-2.80M	-2.07M	-469.80K	-200.00K
	EBIT
-23.77M	-19.94M	-31.11M	-25.74M	-19.20M
	EBITDA
-23.77M	-16.30M	-32.50M	-25.74M	-19.00M
	Net Income Common Stockholders
-26.90M	-21.29M	-38.18M	-25.65M	-19.20M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.14M	3.20M	645.20K	25.35M	10.15M
	Total Assets
8.54M	12.17M	11.97M	30.73M	12.83M
	Total Debt
14.57M	15.54M	9.41M	454.50K	468.00K
	Net Debt
13.43M	12.34M	8.77M	-24.90M	-9.68M
	Total Liabilities
21.13M	21.29M	17.74M	3.41M	1.47M
	Stockholders Equity
-12.59M	-9.12M	-5.77M	27.32M	11.36M
Cash Flow		Free Cash Flow
-19.82M	-21.43M	-28.63M	-22.22M	-7.58M
	Operating Cash Flow
-19.46M	-21.23M	-23.75M	-20.32M	-6.13M
	Investing Cash Flow
-366.00K	-206.60K	-4.87M	-1.81M	-1.46M
	Financing Cash Flow
18.41M	23.99M	3.90M	37.34M	15.81M

Kiromic Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRBP, the sentiment is Negative. The current price of 0.1 is below the 20-day moving average (MA) of 0.82, below the 50-day MA of 1.09, and below the 200-day MA of 1.40, indicating a bearish trend. The MACD of -0.32 indicates Positive momentum. The RSI at 23.63 is Positive, neither overbought nor oversold. The STOCH value of 7.51 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KRBP.

Kiromic Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMMP	55 Neutral	$273.04M	―	-31.16%	―	―	15.17%
CLDX	53 Neutral	$1.30B	―	-23.20%	―	24.49%	5.14%
Sector *	52 Neutral	$5.14B	3.39	-43.55%	2.83%	16.49%	-0.19%
ADCT	46 Neutral	$132.90M	―	123.38%	―	1.84%	43.40%
ADAP	45 Neutral	$75.55M	―	-273.36%	―	883.05%	62.93%
IOVA	39 Underperform	$644.49M	―	-51.85%	―	11070.12%	32.07%
KRBP	25 Underperform	$265.35K	―	271.16%	―	―	-4.26%